Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251797 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
A Phase 1 study of Cancer and Brain and Nervous System, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00251797 is a Phase 1 study of Cancer and Brain and Nervous System that has completed, run by University of New Mexi. The registered enrollment target is 10 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00251797, a Phase 1 study of Cancer and Brain and Nervous System, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG Thalidomide
Study Locations (1)
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2000-03 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251797
The ClinicalTrials.gov registry entry for NCT00251797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Irinotecan is the first listed.
NCT00251797 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT00251797 about?
NCT00251797 is a clinical study titled "A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors". The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the...
What is the current status of trial NCT00251797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2000-03. Estimated completion is 2006-06.
What conditions does trial NCT00251797 study?
This clinical trial studies the following conditions: Cancer, Brain and Nervous System.
What interventions are being tested in trial NCT00251797?
The interventions under investigation include: Irinotecan (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00251797?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00251797 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.